Editorial: Community series in immunotherapy with checkpoint inhibitors for non-small cell lung cancer, colon cancer, and esophageal cancer, volume II.
作者信息
Li Yueyi, Wang Yusha, Gao Jinsheng, Tan Keqin, Frey Benjamin, Gaipl Udo S, Shi Hubing, Ma Xuelei
机构信息
Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
People's Hospital of Yilong County, Nanchong, Sichuan, China.
出版信息
Front Immunol. 2023 Jul 3;14:1222675. doi: 10.3389/fimmu.2023.1222675. eCollection 2023.
Abstract
摘要
相似文献
1
Editorial: Community series in immunotherapy with checkpoint inhibitors for non-small cell lung cancer, colon cancer, and esophageal cancer, volume II.社论：非小细胞肺癌、结肠癌和食管癌免疫检查点抑制剂治疗社区系列，第二卷。
Front Immunol. 2023 Jul 3;14:1222675. doi: 10.3389/fimmu.2023.1222675. eCollection 2023.
2
Recent advances and challenges of immune checkpoint inhibitors in immunotherapy of non-small cell lung cancer.免疫检查点抑制剂在非小细胞肺癌免疫治疗中的最新进展和挑战。
Int Immunopharmacol. 2020 Aug;85:106613. doi: 10.1016/j.intimp.2020.106613. Epub 2020 May 22.
3
[Cost Effectiveness and Health Economics of Immune Checkpoint Inhibitors for Non-Small Cell Lung Cancer].免疫检查点抑制剂用于非小细胞肺癌的成本效益与卫生经济学
Gan To Kagaku Ryoho. 2018 May;45(5):781-784.
4
Immunotherapy in advanced non-small-cell lung cancer with mutations.携带 突变的晚期非小细胞肺癌的免疫治疗。
Immunotherapy. 2020 Nov;12(16):1195-1207. doi: 10.2217/imt-2020-0148. Epub 2020 Sep 27.
5
[Application Progress of Immune Checkpoint Inhibitors
in Oncogene-driven Advanced Non-small Cell Lung Cancer].[免疫检查点抑制剂在癌基因驱动的晚期非小细胞肺癌中的应用进展]
Zhongguo Fei Ai Za Zhi. 2021 Mar 20;24(3):188-195. doi: 10.3779/j.issn.1009-3419.2021.101.04.
6
The combination of immune checkpoint inhibitors and chemotherapy in advanced non-small-cell lung cancer: the rational choice.免疫检查点抑制剂联合化疗治疗晚期非小细胞肺癌：合理选择。
Immunotherapy. 2022 Feb;14(2):155-167. doi: 10.2217/imt-2021-0014. Epub 2021 Dec 6.
7
The role of ERBB4 mutations in the prognosis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors.ERBB4 突变在免疫检查点抑制剂治疗晚期非小细胞肺癌中的预后作用。
Mol Med. 2021 Oct 7;27(1):126. doi: 10.1186/s10020-021-00387-z.
8
PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.PD-1/PD-L1 阻断疗法在晚期非小细胞肺癌中的应用：现状与未来方向。
Oncologist. 2019 Feb;24(Suppl 1):S31-S41. doi: 10.1634/theoncologist.2019-IO-S1-s05.
9
Chemo and Immuno-Therapeutic Options for Nonsmall Cell Lung Cancer Lung Cancer.非小细胞肺癌的化疗和免疫治疗选择 肺癌。
Surg Clin North Am. 2022 Jun;102(3):493-498. doi: 10.1016/j.suc.2022.02.005.
10
[Evaluation of Response to Immune Checkpoint Inhibitor Monotherapy or
Combination with Chemotherapy for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression].[晚期非小细胞肺癌且PD-L1高表达患者对免疫检查点抑制剂单药治疗或联合化疗反应的评估]
Zhongguo Fei Ai Za Zhi. 2021 Mar 20;24(3):161-166. doi: 10.3779/j.issn.1009-3419.2021.103.02.
本文引用的文献
1
Clinical outcomes of immune checkpoint inhibitors to treat non-small cell lung cancer patients harboring epidermal growth factor receptor mutations.免疫检查点抑制剂治疗携带表皮生长因子受体突变的非小细胞肺癌患者的临床结局。
BMC Pulm Med. 2023 May 5;23(1):158. doi: 10.1186/s12890-023-02466-9.
Zotero 插件